Crizotinib (PF-02341066)

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma

Conditions

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma, Locally Advanced and/or Metastatic Clear Cell Sarcoma, Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma

Trial Timeline

Sep 1, 2012 → Oct 30, 2022

NCT ID

NCT01524926

About Crizotinib (PF-02341066)

Crizotinib (PF-02341066) is a phase 2 stage product being developed by Pfizer for Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01524926. Target conditions include Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01524926	Phase 2	Completed	Sep 1, 2012	Oct 30, 2022	Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma

Competing Products

20 competing products in Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	52
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
NBTXR3	Nanobiotix	Phase 1/2	36
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
zolbetuximab	Astellas Pharma	Pre-clinical	23
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	77
enfortumab vedotin (EV)	Astellas Pharma	Pre-clinical	23
zolbetuximab	Astellas Pharma	Pre-clinical	23
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	77
ASP3082	Astellas Pharma	Phase 2	52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	77
ASP1948	Astellas Pharma	Phase 1	33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )	Sun Pharmaceutical	Phase 2	52

Other Products from Pfizer